Document is current
Any future updates will be listed below
-
Authors
Othman, Tamer https://orcid.org/0000-0001-6376-4495
Lowsky, Robert
Richman, Carol
Hoeg, Rasmus
Abedi, Mehrdad https://orcid.org/0000-0003-4640-0977
Tuscano, Joseph https://orcid.org/0000-0002-0522-1406
-
Funding
Funding for this research was provided by:
Acrotech Biopharma
- License Information
-
More Information
Article History
Received: 17 April 2023
Revised: 8 June 2023
Accepted: 19 June 2023
First Online: 30 June 2023
Competing interests
: MA—Speakers bureau for Gilead (Kite), BMS, and AbbVie; Advisory board for BMS. TO, RL, CR, RT, JT have no conflicts of interest to disclose.
